About
The Opportunity
- Pharmaceutical industry is moving away from early discovery research
But it needs to maintain its pipeline - $35 billion of public funding to fuel biomedical research each year
Thousands of worthy discoveries never make it out of academia - Legacy value chain models from university through biotechnology
company formation have resulted in an unsustainable return-on-capital
placed onto the healthcare system
The BioPontis Alliance Solution:
- Ensure predictable and facilitated disclosures from University Alliance Partners
- Identify discoveries that have potential to be developed into therapeutic applications
- Select highly innovative scientific assets for development and employ the most advanced translational research tools available.
- Maximize the use of capital and foster more innovation by investing in a portfolio of R&D projects, NOT in a portfolio of New Companies
- Utilize industry vetted practices during feasibility development
